The global pain management devices market size is expected to reach USD 9.3 billion by 2026 registering a CAGR of 7.6%, according to a new study by Grand View Research, Inc. Rising prevalence of diabetes, coupled with increasing geriatric population base across the globe, is the major factor augmenting the growth of this market. Preference for pain management devices over oral drugs and surgical interventions is also likely to be a high impact rendering driver for the market over the forecast period.
The global market is expected to witness strong growth as a result of various technological advancements in this field. These advancements include the advent of products such as electrode-based wearable automatic transcutaneous electrical nerve stimulators, which provide peripheral pain management in a 60-minute run cycle.
Neurostimulation devices are more efficient than traditional methods as they show a sustained reduction in pain. Additionally, traditional therapy involves intake of medicines that could result in many adverse effects. Such equipment is widely used to manage neuropathic pain as spinal cord stimulators yield the best results. Moreover, these devices offer a customized level of stimulation depending on the activities undertaken by the patient in a day.
North America was the largest regional market in 2018 and held around half of the global revenue owing to the increased number of people affiliated with pain and thereby requiring management devices. The region is expected to maintain its dominance throughout the forecast years on account of presence of sophisticated healthcare infrastructure and rising adoption of advanced equipment by healthcare professionals and patients over conventional treatment therapies.
To request a sample copy or view summary of this report, click the link below:
Further key findings from the study suggest:
By product, neurostimulation led the global market in 2018, accounting for a revenue share of more than 60.0%. These devices have higher preference over traditional technologies due to their higher efficiency in terms of providing relief for a longer duration
The radiofrequency ablation segment is expected to witness the highest CAGR from 2019 to 2026. Rising usage of these devices to cure cancer is the major factor driving their adoption. Long-term relief from cancer pain is also a high impact rendering driver for this segment
Key companies in the global pain management devices market include B Braun Melsungen AG.; Baxter International, Inc.; Boston Scientific Corp.; Codman and Shurtleff; DJO Global LLC; Pfizer, Inc.; Medtronic Plc; Smiths Medical; Stryker Corp.; and St. Jude Medica.
Grand View Research has segmented the global pain management devices market on the basis of the product, application, and region:
Pain Management Devices Product Outlook (Revenue, USD Million, 2014 - 2026)
Transcutaneous Electrical Nerve Stimulators (TENS)
Radiofrequency Ablation (RFA)
Analgesic Infusion Pumps
Intrathecal Infusion Pumps
External Infusion Pumps
Spinal Cord Stimulators
Deep Brain Stimulators
Pain Management Devices Application Outlook (Revenue, USD Million, 2014 - 2026)
Facial & Migraine
Musculoskeletal Disorders (MSDs)
Pain Management Devices Regional Outlook (Revenue, USD Million, 2014 - 2026)
Avail customized purchase options to meet your research needs:
Get your queries resolved from an industry expert. Request for a free product review before report purchase.
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.
"The quality of research they have done for us has been excellent..."